...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: Outcome of Renal Transplantation in Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis
【24h】

The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: Outcome of Renal Transplantation in Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis

机译:荷兰血管炎移植(DUTRAVAS)研究:抗中性粒细胞胞浆抗体相关性肾小球肾炎的肾脏移植结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background. Data on the outcome of renal transplantation in antineutrophil cytoplasmic antibody-associated glomerulonephritis (AAGN) patients are still limited. In particular, how disease recurrence in the renal allograft defines graft outcome is largely unknown. Therefore, we conducted a multicenter observational clinical and histopathological study to establish recurrence rate of AAGN in the allograft and the impact of recurrence on allograft survival. Methods. Using the nationwide Dutch Pathology Registry (PALGA), we retrospectively collected clinical and histopathological data of consecutive AAGN patients who had developed end-stage renal failure and received a kidney allograft in 1 of 6 Dutch university hospitals between 1984 and 2011. Transplant biopsies were scored using the Banff '09 classification. Renal disease recurrence was scored using the histopathological classification of AAGN. Results. The posttransplantation recurrence rate of AAGN was 2.8% per patient year, accumulating to recurrence in a total of 11 of 110 AAGN patients within the first 5 years after transplantation. Four of these 11 patients lost their graft, with 1-year and 5-year graft survival rates of 94.5% and 82.8%, respectively. By multivariate analysis, AAGN recurrence was independently associated with subsequent graft loss. Conclusions. In this study in 110 Dutch patients, the recurrence rate of AAGN within 5 years after kidney transplantation appeared slightly higher than in previous reports. Moreover, recurrence of AAGN contributed independently to kidney allograft loss, emphasizing the importance of clinical vigilance, because early treatment might be critical to rescuing the allograft.
机译:背景。抗中性粒细胞胞浆抗体相关性肾小球肾炎(AAGN)患者的肾移植结局数据仍然有限。特别地,在肾脏同种异体移植中疾病复发如何定义移植物预后很大程度上是未知的。因此,我们进行了多中心观察性临床和组织病理学研究,以确定同种异体移植物中AAGN的复发率以及复发对同种异体移植物存活的影响。方法。我们使用全国荷兰病理注册中心(PALGA)回顾性收集了1984年至2011年间荷兰6家大学医院中的1家发生终末期肾衰竭并接受了肾脏同种异体移植的连续AAGN患者的临床和组织病理学数据。对移植的活组织检查进行了评分使用班夫'09分类。使用AAGN的组织病理学分类对肾脏疾病复发进行评分。结果。 AAGN的移植后复发率为每患者每年2.8%,在移植后的前5年内,总共有110名AAGN患者中有11名复发。这11名患者中有4名失去了移植物,其1年和5年移植物存活率分别为94.5%和82.8%。通过多变量分析,AAGN复发与随后的移植物丢失独立相关。结论。在这项针对110名荷兰患者的研究中,肾移植后5年内AAGN的复发率似乎比以前的报道略高。此外,AAGN的复发是肾脏同种异体移植损失的独立原因,强调了临床警惕的重要性,因为早期治疗对于挽救同种异体移植至关重要。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号